Oxford Brookes Business School

Investing in Women-led Start-ups and Spinouts

This event has now finished. Please see our events website for details of upcoming events at Brookes.

Investing in Women-led Start-ups and Spinouts

Who this event is for

  • Everyone


Online event


Find out how we can increase the number of investment opportunities which women of founding university spinout companies receive.

We invite you to join us to hear from a panel of experts how we can increase the number of women founding university spinout companies from investors' perspective. 

Speaker profiles:


Julie Silvester

Julie has worked at The FSE Group for 15 years and is responsible for all investment activity. Julie has made more than 30 investments and has been an FSE board representative at 14 portfolio companies. In 2008 Julie established FSE’s first equity fund (The South East Seed Fund) partnering with Buckinghamshire New University, Oxford Brookes University, The University of Reading, University of Brighton and University of Sussex.


Rebecca Todd

Rebecca invests in early-stage life science and medical technology companies. She began venture investing in 2006 while at Oxford Capital, where she took responsibility for the Oxford Gateway Funds’ investments into healthcare and life science companies. She went on to become Director, Healthcare Ventures at Imperial Innovations (now part of IP Group). Her earlier career was as a marketing consultant to pharmaceutical and life science technology companies. Rebecca has a PhD in Genetics from Nottingham University and an MBA from Oxford University. She joined Longwall Ventures in 2017 after a sabbatical break spent exploring South America in a campervan.


Sarah Haywood

Sarah Haywood is Managing Director for Advanced Oxford, a not-for-profit membership group for innovation-based companies and organisations. Advanced Oxford is research-led, providing analysis, insight and a united voice on issues affecting the development of the innovation ecosystem in the Oxford region. Sarah is also Executive Director with MedCity and on the board of VentureFest Oxford.Sarah started her career in the NHS, worked in the pharmaceuticals industry and was a senior civil servant within the Department for Business. An advocate for flexible working, she was recognised amongst the Timewise Power 50 Award winners in 2017.Sarah studied at the University of Oxford, has an MA in Human Resources Management, and is a Chartered Fellow of the Chartered Management Institute.


Claudio D’Angelo

Claudio is the founder and Managing Director of Spex Capital and sits on the Board of the Chelsea and Westminster Foundation Innovation Hub. Spex Capital is a digital health and med-tech investment management firm specialising in advancing disruptive early-stage ventures to deliver breakthroughs in healthcare systems globally. Previously Claudio co-founded and managed Ryse Asset Management LLP, also a digital health and med-tech specialised VC. From 2009 to 2014 Claudio was the sole Director of Gauss Investments Ltd. Previously he was Head of Sales in Equity and Derivatives to Europe and Middle East at BNP Paribas in London, and a member of the Management Committee. From 2000 2005, he worked at Lehman Brothers London in Equity Finance as Head of Sales to Europe. Claudio holds a degree in Economics from Bologna University, Italy and an Executive Master’s programme in finance at INSEAD, Fontainebleau, France.


Claire Brown

Claire is currently interim CIO at Oxford Science Innovation. Claire also sits on the Board of Dark Blue Therapeutics. Prior to OSI Claire headed up Investment at BioCity where she developed the strategy, created a number of early stage ventures and supported companies as a Board member in areas such as Therapeutics (Rinri TX, Fast BioPharma and BiVictriX), Synthetic Biology (NanoSyrinX) and Precision Medicine (Kinomica). Claire has previously worked in AstraZeneca supporting early drug repositioning and strategy including within AZ’s corporate VC group, MedIVentures, after spending 11 years in the USA at Sanofi- Genzyme and UCB Pharma in a variety of roles from Scientific leadership to Project management. She holds a Ph.D. and Honours degree in Physiology, an MBA and is certified in Investment Management.